Older Primary Care Drugs Matter – For Cash, And For Emerging Market Access
Europe's mid-sized pharma may be going specialist like much of the rest of the industry, including some of the biggest companies
You may also be interested in...
SHANGHAI- The French firm Ipsen and Singapore's Invida have forged an exclusive distribution and promotion deal covering a number of Ipsen's oncology and endocrinology drugs in select South-East Asian countries. The agreement is expected to help expand the geographical reach of Ipsen's specialty-care portfolio in the Asia Pacific region
As Ipsen shifts away from an emphasis on primary care and toward specialty care therapies – a move straight out of Big Pharma’s playbook – endocrinology will become a pillar of its specialty care pipeline.
For about $670 million, GSK acquires UCB drugs and infrastructure in several dozen non-BRIC markets.